Pharmerica Corp: (NYSE: PMC)

$14.04

0.03 (0.21%)

Volume 293,988

May 17 04:01 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		14.02 - 14.14
	
		52wk Low - High
		9.03 - 15.42
	
		Previous Close
		14.01
	
		Avg. Volume
		303,516
	
		Industry
		RETAIL-DRUG STR
	
		Market Cap
		414.77 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.62
	
		PE (Forward)
		10.45
	
		Current Year Est.
		1.34
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		25 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/8/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            10.45
                        
                            PEG Ratio
                            1.05
                        
                            Current Year Est.
                            1.34
                        
                            Current Quarter Estimate
                            0.31
                        
                            Most Accurate Estimate
                            0.31
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            1.40
                        
                            Expected Earnings Growth
                            10.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation. As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues.   
Full PMC Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
PMC Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.31	0.30	1.34	1.48
Number of Estimates	3	3	3	3
Low Estimate	0.30	0.26	1.28	1.39
High Estimate	0.32	0.34	1.40	NA
Year Ago EPS	0.32	0.33	1.27	1.34
EPS Growth	-3.12%	-10.10%	5.77%	10.17%

More PMC Estimates

Average Earnings Estimates for PMC

EPS Growth for PMC

Industry Analysis

Name	Symbol	Previous Close
PHARMERICA CORP	PMC	14.04
CHINA NEPSTAR	NPD	1.70
CVS CAREMARK CP	CVS	59.44
GNC HOLDINGS	GNC	45.63
HERBALIFE LTD	HLF	44.44
RITE AID CORP	RAD	2.79
AMERISOURCEBRGN	ABC	54.99
CARDINAL HEALTH	CAH	47.79
MCKESSON CORP	MCK	116.89
WALGREEN CO	WAG	49.61

Sector:Retail-Wholesale>> Industry:RETAIL-DRUG STR

COMPARE TICKER vs. Its Peers

Zacks Commentary

McKesson Earnings Down in 4Q

May 08, 2013

OCR Beats on Earnings Est; Misses Rev

Apr 25, 2013

Roundtable Top Picks for the Week of Apr. 22nd

Apr, 22 2013 00:00

Zacks Investment Ideas feature highlights: PharMerica, First Defiance Financial, American Railcar Industries and Big 5 Sporting Goods

Apr 15, 2013

4 Cheap Small Cap Stocks

Apr, 12 2013 00:00

4 Cheap Small Cap Stocks

Apr, 11 2013 00:00

Low March Comps Hurt RAD's Shares

Apr 05, 2013

CVS/pharmacy Introduces New App

Apr 02, 2013

More PMC Zacks Commentary

Financials

EPS TTM	1.40
Sales	1,833
Net Income	28
Price/Earnings	10.03
Price/Book	0.91
Price/Cash Flow	5.94
Price/Sales	0.23

More PMC Financials

News

PharMerica Earnings Hindsight: Up 9.9% in Last 17 Days (PMC) - Financial News Network Online - Earnings Lookback

May 18, 2013

China Medicine has the Lowest Price to Book Ratio in the Health Care Distributors Industry (CHME, PMC, OMI) - Financial News Network Online - News Corner

May 16, 2013

Lowest P/E Ratio in the Health Care Distributors Industry Detected for PharMerica (PMC, CAH, MCK) - Financial News Network Online - News Corner

May 15, 2013

MWI Veterinary Supply is Among the Companies in the Health Care Distributors Industry With the Highest EBITDA Growth (MWIV, MCK, PMC) - Financial News Network Online - News Corner

May 14, 2013

PharMerica to Present at the Bank of America Merrill Lynch 2013 Health Care Conference - Businesswire

May 14, 2013

Lowest PEG Ratio in the Health Care Distributors Industry Detected for PharMerica (PMC, CAH, MCK) - Financial News Network Online - News Corner

May 10, 2013

PharMerica Makes a Move: Up 1.9% - Financial News Network Online - Market Movers

May 6, 2013

PharMerica Reports Results for the First Quarter of 2013 - Close-Up Media

May 6, 2013

See All News Stories on PMC

Broker Recommendations

Current ABR	2.43
ABR (Last Week)	2.43
# of recs in ABR	7
Average Target Price	17.00
Industry Rank by ABR	25 out of 265
Rank in Industry	6 out of 11

More PMC Broker Recommendations

Day Low - High	14.02 - 14.14
52wk Low - High	9.03 - 15.42
Previous Close	14.01
Avg. Volume	303,516
Industry	RETAIL-DRUG STR
Market Cap	414.77 M
Div - Yield	0.00 - 0.00
Beta	0.62
PE (Forward)	10.45
Current Year Est.	1.34
Quarterly Earnings ESP	0.00%

PE (Forward)	10.45
PEG Ratio	1.05
Current Year Est.	1.34
Current Quarter Estimate	0.31
Most Accurate Estimate	0.31
Earnings ESP	0.00%
Next Earnings Report Date	08-08-2013
EPS Last Year	1.40
Expected Earnings Growth	10.00%

Username: Password:

Remember me [?]

Pharmerica Corp: (NYSE: PMC)

$14.04

0.03 (0.21%)

Volume 293,988

May 17 04:01 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description